---
title: "Baidu Non-GAAP EPADS of $1.06 misses by $0.40, revenue of $4.62B misses by $120M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296203425.md"
description: "Baidu's Q2 results missed expectations, with Non-GAAP EPS of $1.06 falling short by $0.40 and revenue of $4.62 billion missing estimates by $120 million. General business revenue declined 4% year-over-year to RMB25.2 billion, while iQIYI revenue dropped 5% to RMB6.3 billion. Adjusted EBITDA stood at RMB6.2 billion with a 20% margin. The company held RMB283.1 billion in cash and investments as of June 30, 2026."
datetime: "2026-08-18T09:16:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296203425.md)
  - [en](https://longbridge.com/en/news/296203425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296203425.md)
generator: "portal-rs"
---

# Baidu Non-GAAP EPADS of $1.06 misses by $0.40, revenue of $4.62B misses by $120M


### Related Stocks

- [IQ.US](https://longbridge.com/en/quote/IQ.US.md)

## Related News & Research

- [iQIYI Announces Second Quarter 2026 Financial Results | IQ Stock News](https://longbridge.com/en/news/296202910.md)
- [iQIYI: Sequential revenue growth and AI-driven content expansion fueled profitability and global reach](https://longbridge.com/en/news/296235524.md)
- [Baidu completes dual-primary listing in Hong Kong and Nasdaq](https://longbridge.com/en/news/297602235.md)
- [LexinFintech Non-GAAP EPADS of $0.11, revenue of $469.71M; gives Q3 outlook](https://longbridge.com/en/news/297466798.md)
- [PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push](https://longbridge.com/en/news/297657742.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**